Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well dasatinib works in treating patients with relapse
small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.